HC Wainwright Issues Negative Estimate for GENB Earnings

Generate Biomedicines Inc (NASDAQ:GENB) – Investment analysts at HC Wainwright dropped their Q2 2026 EPS estimates for shares of Generate Biomedicines in a report released on Friday, May 8th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.51) for the quarter, down from their previous estimate of ($0.48). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. HC Wainwright also issued estimates for Generate Biomedicines’ Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.54) EPS, FY2026 earnings at ($2.11) EPS, Q1 2027 earnings at ($0.57) EPS, Q2 2027 earnings at ($0.50) EPS, Q3 2027 earnings at ($0.51) EPS, Q4 2027 earnings at ($0.51) EPS and FY2027 earnings at ($2.09) EPS.

Generate Biomedicines (NASDAQ:GENB) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

Several other equities research analysts have also recently commented on the stock. Zacks Research upgraded shares of Generate Biomedicines to a “hold” rating in a research report on Wednesday, March 25th. Wall Street Zen cut shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday. The Goldman Sachs Group assumed coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating for the company. Finally, Morgan Stanley assumed coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating and a $20.00 price target for the company. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Generate Biomedicines Stock Up 5.2%

Shares of NASDAQ:GENB opened at $14.37 on Tuesday. Generate Biomedicines has a one year low of $11.00 and a one year high of $15.89. The business’s 50 day simple moving average is $12.68.

Trending Headlines about Generate Biomedicines

Here are the key news stories impacting Generate Biomedicines this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $25 price target on Generate Biomedicines, signaling continued upside confidence despite the forecast tweaks. Generate Biomedicines stock page
• Positive Sentiment: The analyst raised Q3 2026 EPS estimates to ($0.52) from ($0.54) and improved Q4 2026 estimates to ($0.54) from ($0.56), suggesting a slightly better operating outlook in parts of 2026. Generate Biomedicines stock page
• Neutral Sentiment: The stock also has support from its current price structure, opening near $14.37 versus a 52-week range of $11.00 to $15.89, which keeps investors focused on whether bullish analyst targets can be justified. Generate Biomedicines stock page
• Negative Sentiment: HC Wainwright cut estimates for Q2 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027, FY2026, and FY2027, reflecting a somewhat softer earnings outlook and likely limiting further upside. Generate Biomedicines stock page
• Negative Sentiment: The company recently reported a Q1 earnings miss, posting ($1.07) EPS versus expectations of ($0.48), which may still be weighing on sentiment. Generate Biomedicines stock page

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.